Super video illustrating how important it is to value staff so that they will give their all

Check out "Can we “Netflix” the broken antibiotics market?" UKCPA Infection Committee @biainfection BSAC Kieran Hand PhD Diane Ashiru, PhD eventbrite.co.uk/e/can-we-netfl… @Eventbrite

Fantastic meeting on new antimicrobial development here in Dublin. Delighted to present NICE, NHS England & UK Government Department of Health & Social Care work on incentivising antimicrobial pipeline using novel value assessment & delinked reimbursement escmid.org/dates_events/e…

Very proud of Lucy judging ice dance Grand Prix final in Turin

🚨 Northern Ireland and Manchester Interstitial Lung Disease Course which will be held on 2nd -3rd March 2023 🚨 #Manchester 🇬🇧 🫁 #ILD #CTD_ILD #PFILD #PostCOVID_ILD #AEILD #MDT 🫁 We look forward to seeing you there! You can see the programme and the link to register below 👇

Delighted to share our publication on the NICE & NHS England project to deliver novel value assessment & reimbursement for new antimicrobial ⁦NICE⁩ ⁦NHS England⁩ trebuchet.public.springernature.app/get_content/9f…

'Can the UK's Netflix payment model boost the antibacterial pipeline?' Great insights on the how the project was devised & developed - sharing lessons learned - from colm leonard and team: pubmed.ncbi.nlm.nih.gov/36646872/ #pullincentives #antibioticresistance #innovation

Retweet as link apparently not working for some . trebuchet.public.springernature.app/get_content/9f…

Can the UK 'Netflix' Payment Model Boost the Antibacterial Pipeline? - PubMed pubmed.ncbi.nlm.nih.gov/36646872/

Questions about the UK Subscription Program for Antibacterials? See our Open Access article out today. Kudos to Team UK for leading the world. link.springer.com/article/10.100… w John H. Rex, MD

We are recruiting healthy volunteers for a trial with INFEX Therapeutics. The full details are below 👇 Contact us to find out how you can #GetInvolvedinResearch @LivHospitalsRI @LivHospitals

Alarming antibiotic resistance discovered in war-torn Ukraine- this is truly frightening, the not so silent pandemic of AMR, 10% resistance to Colistin! medicalxpress.com/news/2023-06-a…

Infex Therapeutics Clinical candidate nominated for COV-X programme 📈COV-X outperforms Pfizer's approved antiviral 🌟Unique target: potential for broad efficacy against new coronaviruses 🦠Emerging resistance to existing Mpro inhibitors infextx.com/clinical-candi… #COVID19

📣 INFEX Therapeutics is on a mission to combat new COVID strains and is searching for a global pharma partner. Read more about their new treatment for COVID variants below ⬇️ bit.ly/45jwo5H

Looks like a super programme, thanks for sharing Chris.

This is scary, warzone superbugs come to visit! Funders, regulators, HTA entities need to facilitate antibiotic pipeline to have necessary armoury to fight this threat. Antimicrobial resistance is not a silent threat. Antimicrobial BioTech needs support harvardpublichealth.org/global-health/…

📊 New data from UK Health Security Agency: Antibiotic-resistant infections in 2023 exceeded pre-pandemic levels An alarming 66,730 serious cases were reported - compared to 62,314 in 2019. 👉gov.uk/government/new…

Novel pathways to combat antimicrobial resistance sorely needed. Its super that with this PACE funding INFEX & the team at Justus-Liebig-University Giessen can now advance this exciting BamA inhibitor project towards clinical trial readiness

Excited to share our licensing deal in India for clinical development of MET-X our novel metallobetalactamase (MBL) inhibitor. MBL mechanism of resistance is an enormous problem in India & SE Asia & a rising problem EU & USA. MBL mechanism is a key pipeline priority for WHO

Very excited to work with Asian ADVANCE-ID network to plan clinical trials of our novel metallo-beta-lactamase (MBL) inhibitor, MET-X. Antimicrobials targeting MBL mechanism of Gram negative bacterial resistance to antibiotics is key gap in pipeline. David Paterson INFEX Therapeutics